Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study.
Yuan-Kai ShiJianying ZhouYanqiu ZhaoBo ZhuLiangming ZhangXingya LiJian FangJianhua ShiZhixiang ZhuangSheng YangDonglin WangHuiqing YuLongzhen ZhangRongsheng ZhengMichael GrecoTingting WangPublished in: BMC medicine (2023)
ClinicalTrials.gov, NCT03386955.